UW Health Technology Assessment Committee
UW Health Technology Assessment Committee
The goal of the Technology Assessment Committee is to facilitate the adoption and use of safe, efficacious, and cost-effective medical device technologies that improve patient care by considering issues related to the safety, efficacy, financial impact, and fit with the programmatic needs and mission of UW Health.
Technologies in place at UW Health will be:
Safe with freedom from danger, risk or injury.
Efficacious with the results of technology having a quantifiable benefit.
Cost-effective with the total cost of the technology supported by the management aim to ensure the maximum benefit is gained for each health care dollar spent.
Technology assessments will include evidence-based scientific, clinical and financial analysis. Technology acquisition decisions will be made in an integrated fashion, with decisions implemented across all UW Health entities. New biomedical device technologies are defined by the following:
- A novel or emerging medical device technology that is not currently in clinical use at UW Health.
- A current or previously used technology (including technology extensions), procedure or device with new applications that is considered novel and/or that has the potential to clinically or financially impact a program or service line.
- A technology or procedure that falls outside of the usual and customary reimbursement practices and has the potential to place the hospital at risk for shouldering the cost of the devices or procedure.
The committee is charged with the following:
- Evaluating biomedical device technologies that are new to the organization including capital equipment, implants and disposable supplies in the hospital or ambulatory settings with a single purchase or total annual expense of $100,000 or greater (including philanthropic donations).
- Involvement in ambulatory technology standardization under the guidance of the ambulatory leadership team.
- Hybrid technologies that are a combination drug/device will be jointly reviewed by the Technology Assessment Committee and the Pharmacy and Therapeutics Committee that is charged with managing medications, formularies, and policies.
- Providing post-acquisition evaluations of acquired technologies to inform future technology assessment and strategic decision making.
- Evaluating requests for loaned, borrowed or trialed equipment as outlined in the UW Hospital and Clinics Evaluation of Capital Clinical Equipment Policy 11.35.
- Evaluating technologies impacting faculty recruitment, retention packages or other investment initiatives.
- Coordinating with Unity Health Insurance in the review of new technologies.
Review of drugs/pharmaceuticals is reviewed by the Pharmacy and Therapeutics Committee. Review of laboratory tests including molecular diagnostics is reviewed and approved by the Clinical Laboratory Committee. The Technology Assessment committee may become involved in a drug or lab request if there is an equipment component or providing consultative review upon request.
Recommendations made by the Technology Assessment Committee regarding technology acquisition are communicated to the requester(s) and the Capital Allocations Committee. Recommendations can include adoption of the technology, adoption with restrictions, deferral with re-review at a later date or denial.
New technologies that are deferred after technology assessment review may still be considered for acquisition based on strategic factors that are not typically included in technology assessment review. These strategically purchased technologies will undergo a post-acquisition evaluation to inform future decision making.
Decisions regarding promotion of new technologies to prospective patients and families will be conducted in consultation with UW Health Marketing and Public Affairs, and all marketing messages will be in alignment with the recommendations from the Technology Assessment Committee.
The Technology Assessment Committee is comprised of a multidisciplinary team that includes staff representation from major clinical specialties, clinicians, financial analysts and administrative leadership. The committee is charged with applying a systematic evidence-based review process to evaluate the clinical, financial and operational aspects of technology adoption. This process is undertaken to evaluate the evidence by which to form conclusions as to the merits of a particular technology. This system-wide committee evaluates the operational needs and clinical benefits while ensuring product standardization across the UW Health system.
The Technology Assessment Committee is chaired by the Senior Vice-President and Chief Operating Officer. Coordination and staffing of the committee is supported by the Business Planning and Analysis Department and the Center for Clinical Knowledge Management. Membership of the committee includes, but is not limited to representation from the following service lines and departments:
- Hospital Administration
- Physician Representatives
- Surgical Services
- Service Line Directors
- Ambulatory Operations
- Clinical Laboratories
- Business Planning and Analysis
- Procurement Services
- Clinical Engineering
- Information Technology
- Risk Management
- Unity Health
- Representatives from other fields as necessary
Selection of Members
Applicants for membership may be nominated by any current committee member or a written request for membership may be submitted to chair of the committee. Membership of the committee will be selected and approved by the chair of the committee and the nominee’s respective department head.
Duties and Responsibilities
The duties of the committee shall include, without limitation, the following:
- Provide surveillance for new technologies in development.
- Review the relative safety, effectiveness, cost and other pertinent factors in deciding which technologies should be considered for adoption.
- Promote interdisciplinary collaboration in understanding and solving mutual issues with regard to products standardization and equipment.
The Technology Assessment Committee is a standing committee that meets on a monthly basis or more frequently as deemed necessary at a time and place determined by the committee chairperson.
The committee shall conduct its business in accordance with this charter and operational procedures. A quorum (defined as a simple majority) must be present to conduct business. Each member shall have one vote on any matter on which the committee votes. At least two physicians must be present to recognize a quorum when voting on issues directly pertaining to the assessment of a technology.
Meeting minutes shall serve as a permanent record of committee proceedings. Recommendations from the committee will be disseminated to the Capital Allocations Committee for integration into the capital decision making process and system-wide planning needs.
Conflict of Interest Disclosure and Management
A conflict of interest declaration must be signed by both the technology assessment committee members and requestors to ensure balance, independence, objectivity and scientific rigor in activities pertaining to the technology assessment process. Committee members must complete a conflict of interest statement annually and as new interest arises. Practitioners will be required to submit a conflict of interest statement with their requests. The formal technology assessment review process will not commence until this declaration is received. Potential conflicts of interest will be identified and managed in accordance with institutional policies and procedures. Conflict of interest management will include, but is not limited to, conflict disclosure, abstention from voting, dismissal during comment and voting period, recusal from requesting and/or participation in the decision-making process.
Charter Review Frequency and History
This charter and membership will be reviewed, updated and approved yearly.
Assessment of technology at UW Health has existed for over forty years in a variety of forms. Originally, evaluation of new devices was performed by the Pharmacy and Therapeutics (P&T) Committee using evidenced-based evaluation methods developed for reviewing drugs. In the early 1990’s an informal group of UWHC physicians and administrators met regularly to discuss emerging medical device technologies, but lacked the administrative power to make decisions. The meeting grew to include all hospitals and major health plans in Madison. By 1995 the group disbanded due to retirement of key members. In 2003, the UWHC Technology Assessment Committee returned, modeling the governance structure that has been successful for the P&T committee and is the foundation for the current Technology Assessment charter. In December of 2014 the Quality Council approved eight guiding principles for the review and endorsement of new technology at UW Health that are reflected in the current 2016 charter.